Objective: To evaluate the effect of brief counseling on patient readiness for behavioral change and cessation/reduction of tobacco and alcohol use. Methods: This clinical trial randomized patients in blocks, stratified by risk factor. Adult smokers or at-risk drinkers undergoing surgical or diagnostic procedures were recruited. Outcome assessments and analyses were blinded. Brief counseling was compared with educational materials for the outcomes progress in stage of change and smoking/alcohol cessation/reduction. Results: Overall, 222 participants were randomly assigned to the intervention group and 218 to the control group. Among them, 28 and 18 patients were lost to follow-up, respectively. Progress in change stage was 94.1% at 1 month in both groups (RR = 1.00; 95%CI 0.95-1.05) and 94.8 vs. 90.5% at 3 months (RR = 1.05; 95%CI 0.99-1.11) in the intervention and control groups, respectively. Smoking cessation and alcohol reduction rates at 3 months were 57.2 vs. 41% (RR = 1.40; 95%CI 1.14-1.71) in the intervention and control groups, respectively. Only brief counseling led to significant differences in smoking cessation (51.4 vs. 35.1%; RR = 1.46; 95%CI 1.12-1.92). Conclusions: Brief counseling and educational materials improved patient motivation for behavioral change, but brief counseling had a greater effect on smoking cessation. Clinical trial registration: NCT03521622

Resumen Introducción: La enfermedad cerebrovascular es causa frecuente de morbimortalidad y, en ese sentido, el consumo de café tiene un impacto cardiovascular, por lo cual es importante evaluar la evidencia respecto a la asociación entre su consumo y la enfermedad cerebrovascular. Objetivo: Evaluar la asociación entre consumo de café y riesgo de morbimortalidad por enfermedad cerebrovascular. Método: Se realizó una búsqueda en las bases Medline, EMBASE, LILACS y Cochrane (enero de 1966 a junio de 2018) y se seleccionaron revisiones sistemáticas y metaanálisis evaluados de forma estandarizada y pareada. Se seleccionaron seis publicaciones. Resultados: Se encontró que el consumo de café en rango moderado (hasta cuatro tazas) se asocia a una reducción del riesgo de enfermedad cerebrovascular (riesgo relativo [RR] = 0.89, intervalo de confianza del 95% [IC95%]: 0.81-0.97, y RR: 0.83, IC95%: 0.75-0.91). Esta protección se mantiene en el subgrupo de mujeres, con reducciones del 13% (IC95%: 0.78-0.97) para una taza, del 16% (IC95%: 0.74-0.95) para dos tazas y 19% (RR: 0.81; IC95%: 0.70-0.93) (IC95%: 0.70-0.93) para cuatro o más tazas. Los hallazgos también son significativos para el subtipo isquémico (RR = 0.80; IC95%: 0.71-0.90). Conclusiones: El consumo de café reduce el riesgo de eventos cerebrovasculares entre un 11% y un 17%, y esto se mantiene en el subgrupo de mujeres y en el subtipo isquémico.

Abstract Introduction: Cerebrovascular disease is a frequent cause of morbidity and mortality and, in this sense, coffee consumption has a cardiovascular impact, which is why it is important to evaluate the evidence regarding the association between its consumption and cerebrovascular disease. Objective: To evaluate the association between coffee consumption and risk of morbidity and mortality due to cerebrovascular disease. Method: A search was carried out in the Medline, EMBASE, LILACS and Cochrane databases (January 1966 to June 2018), selecting systematic reviews and meta-analyzes evaluated in a standardized and paired way. Six publications were selected. Results: it was found that the consumption of coffee in a moderate range (up to 4 cups) is associated with a reduction in the risk of cerebrovascular disease (relative risk [RR] = 0.89, 95% confidence interval [95% CI]: 0.81- 0.97, and RR = 0.83, 95% CI: 0.75-0.91). This protection is maintained in the subgroup of women, with reductions of 13% (95% CI: 0.78-0.97) for a cup, 16% (95% CI: 0.74-0.95) for two cups, and RR = 0.81 (95% CI: 0.70-0.93) for four or more cups. The findings are also significant for the ischemic subtype (RR = 0.80; 95% CI: 0.71-0.90). Conclusions: Coffee consumption reduces the risk of cerebrovascular events between 11% and 17%, and this is maintained in the subgroup of women and in the ischemic subtype.

Resumen Objetivo Analizar y sintetizar la evidencia sobre el efecto del consumo habitual de café en la aparición de enfermedad cardiovascular. Métodos Se realizó una evaluación crítica de la literatura basada en metaanálisis y revisiones sistemáticas publicadas en Medline, EMBASE, Cochrane Database of Systematic Reviews y LILACS (enero 1966 a junio 2018). La búsqueda, selección y extracción de información fue llevada a cabo por una pareja de investigadores. La calidad de los manuscritos fue evaluada con AMSTAR. Resultados Se analizaron cuatro revisiones sistemáticas que consideraron como desenlaces enfermedad coronaria, riesgo cardiovascular e infarto del miocardio; para el primer y segundo desenlace se encontró una reducción del riesgo con consumo de 3-4 tazas/día (RR=0,90; IC95% 0,84-0,9; p de heterogeneidad=0,02 y RR=0,85; IC95% 0,80-0,90; p de heterogeneidad=0,09); para 1-2 tazas/día (RR=0,89; IC95% 0,85-0,94; p de heterogeneidad=0,83 y RR=0,89; IC95% 0,84-0,94; p de heterogeneidad=0,09) respectivamente. Para infarto agudo de miocardio se reportó un aumento del riesgo en hombres con consumo de 3-4 tazas/día (OR=1,75; IC95% 1,44-2,14; p de heterogeneidad=0,005) y de ≥ 4 tazas/día (OR=2,01; IC95% 1,7-2,36; p de heterogeneidad<0,001). Conclusiones Los consumos leves y moderados de café tienen un efecto neutro o de reducción del riesgo cardiovascular y de enfermedad coronaria; en contraste, el riesgo de infarto agudo de miocardio se incrementa con consumos mayores o iguales a 3 tazas/día en hombres. Se recomienda el consumo de hasta 3 tazas de café día y se desaconsejan consumos mayores, especialmente en hombres.

Abstract Objective To analyse and summarise the evidence on the effect of regular coffee drinking on the appearance of cardiovascular disease. Methods A critical review of the literature was carried out based on a meta-analysis and systematic reviews published in MedLine, EMBASE, Cochrane Database of Systematic Reviews, and LILACS (January 1966 to June 2018). The search, selection, and extraction of the information were performed by two investigators. The quality of the manuscripts was evaluated using AMSTAR. Results An analysis was made of 4 systematic reviews that considered coronary disease, cardiovascular risk, and myocardial infarction as outcomes. For the first and second outcomes, a reduction in risk was found with consuming 3-4 cups/day (RR=0.90; 95%CI; 0.84-0.9; P=.02, and RR=0.85; IC95% CI; 0.80-0.90; P=.09); for 1-2 cups/day (RR=0.89; 95%CI; 0.85-0.94; P=.83, and RR=0.89; 95%CI; 0.84-0.94; P=.09), respectively. As regards myocardial infarction, an increase in risk was reported with consuming 3-4 cups/day (OR=1.75; 95%CI; 1.44-2.14; P=.005) and ≥ 4 cups/day (OR=2.01; IC95%CI; 1.7-2.36; P<.001). Conclusion Mild and moderate consumption of coffee has a neutral effect or a reduction in cardiovascular risk and coronary disease. On the other hand, the risk of myocardial is increased with drinking more or equal to 3 cups/day in men. The drinking of up to 3 cups of coffee/day is recommended, and it is not advised to drink more, especially in men.

ABSTRACT The objective of this study was to establish the relationship between habitual coffee consumption and all-cause and cardiovascular mortality. A systematic review was conducted using Medline, EMBASE, LILACS and Cochrane databases. Systematic reviews and meta-analysis were selected and analyzed. From 181 systematic reviews, 74 were selected by title and summary; after eliminating duplicates. According to the quality score of the AMSTAR tool, five articles were selected for information extraction and analysis. Moderate coffee consumption (3 or 4 cups) decreased overall mortality, compared to non-consumption (RR= 0.83, 95% CI: 0.79-0.88; I2= 83% for 3 cups, and RR= 0.84, 95% CI: 0.82-0.87; I2= 58% for 4 cups) and minimum consumption (RR= 0.88, 95% CI: 0.84-0.93; I2= 68.7% for 4 cups, and RR= 0.87, 95% CI: 0.83-0.91; I2= 59.8% between 3 and 4 cups). Cardiovascular mortality was reduced when compared to non-consumption, for 4 cups (RR= 0.80, 95% CI: 0.74-0.86; I2= 58%) and (RR= 0.83, 95% CI: 0.75-0.92; I2= 92%), and for 3 cups (RR= 0.81, 95 CI: 0.72-0.90; I2= 92%; RR= 0.79, 95% CI: 0.74-0.84; I2= 58%). In conclusion, habitual coffee consumption between 3 and 4 cups reduces the risk of all-cause and cardiovascular mortality.

RESUMEN El objetivo de este estudio fue establecer la relación entre consumo habitual de café y la mortalidad general y cardiovascular. En una búsqueda sistemática en Medline, EMBASE, LILACS y Cochrane se seleccionaron y analizaron revisiones sistemáticas y meta-análisis por una pareja de investigadores. De 181 referencias, 74 fueron seleccionadas por título y resumen; luego de eliminar duplicados y según el puntaje de calidad obtenido por AMSTAR, se consideraron 5 artículos para extracción y análisis. El consumo moderado de café (3 o 4 tazas) disminuye la mortalidad general, tanto comparado con el no consumo (RR= 0,83; IC95%: 0,79-0,88; I2= 83% para 3 tazas, y RR=0,84 IC95%: 0,82-0,87; I2= 58% para 4), como con un consumo mínimo (RR= 0,88; IC95%: 0,84-0,93; I2= 68,7% para 4 tazas, y RR= 0,87; IC95%: 0,83-0,91; I2= 59,8% para consumo entre 3 y 4 tazas). La mortalidad cardiovascular se reduce si se compara con el no consumo, para 4 tazas (RR= 0,80; IC95%: 0,74-0,86; I2= 58%) y (RR= 0,83; IC95%: 0,75-0,92, I2 = 92%) y para 3 tazas (RR= 0,81; IC95%: 0,72-0,90; I2= 92%) y RR (0,79; IC95% 0.74-0.84; I2= 58%). Como conclusión, el consumo habitual de 3 y 4 tazas de café reduce la mortalidad general y cardiovascular.

Resumen Introducción: El café es una de las bebidas más consumidas en el mundo, aunque no están claramente establecidos sus efectos en la salud. En particular, aún hay controversia sobre sus efectos cardiovasculares. El objetivo de este trabajo es sintetizar evidencia acerca de los efectos del consumo habitual de café, en la salud cardiovascular. Métodos: Se llevó a cabo una revisión de revisiones sistemáticas de la literatura, de artículos obtenidos de las bases Medline, Embase, Cochrane y LILACS, publicados en inglés, español, francés o portugués. La búsqueda fue complementada manualmente con las referencias de las revisiones incluidas. Una pareja de investigadores seleccionó y extrajo información de manera independiente, y las discrepancias se resolvieron por consenso. Las revisiones incluidas se clasificaron según el año de publicación, desenlaces, diseño de los estudios primarios y calidad. Se utilizó el instrumento Assessing Methodological Quality for Systematic Reviews para calificar la calidad, y la información se sintetizó en formatos sistematizados. Discusión: La revisión sintetizó la evidencia del efecto del café sobre la salud cardiovascular y estimó la relación dosis-respuesta.

Abstract Introduction: Coffee is one of the most consumed beverages worldwide and its effect on health has not been clearly established. There is a special controversy about its effects on the cardiovascular system. The objective of this work is to synthesize the evidence on the effects of habitual coffee consumption on cardiovascular health. Methods: Review of systematic reviews of the literature published in English, Spanish, French and Portuguese in biomedical databases (Medline, Embase, Cochrane, and Lilacs). The search will be supplemented with manual searching of references of the included reviews. The information will be selected and extracted separately by two researchers, and disagreements will be resolved by consensus. The included reviews will be grouped by year of publication, outcomes, design of original studies and quality. The study will apply the Assessing Methodological Quality for Systematic Reviews checklists to assess the methodological quality of the systematic reviews. The information will be synthesized in systematized formats. Discussion: The review of reviews will synthesize the evidence of the effect of coffee on cardiovascular health and estimate the dose-response relationship.